Mia Vanessa Pinto-ochoa, AGACNP-BC Clinical Nurse Specialist - Acute Care Medicare: Not Enrolled in Medicare Practice Location: 4313 Birdseye Way, Elk Grove, CA 95758 Phone: 916-803-6338 |
Mary N Wachira, Clinical Nurse Specialist - Medical-Surgical Medicare: Not Enrolled in Medicare Practice Location: 10097 Avocado Way, Elk Grove, CA 95757 Phone: 916-833-8989 |
Mr. Darwin Sacdalan, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 7137 Lyndale Cir, Elk Grove, CA 95758 Phone: 909-565-3672 |
Angelica Grace Fernandez, Clinical Nurse Specialist - Long-Term Care Medicare: Not Enrolled in Medicare Practice Location: 9449 Pinot Blanc Ct, Elk Grove, CA 95624 Phone: 916-430-6989 |
Dr. Charles Wayne Williams, CNS.,NP. Clinical Nurse Specialist - Gerontology Medicare: Not Enrolled in Medicare Practice Location: 5040 Brabant Ct, Elk Grove, CA 95757 Phone: 916-752-1273 Fax: 916-676-4865 |
News Archive
Smith & Nephew Orthopaedics Division today announces the global launch of its VLP™ FOOT Variable-angle Locked Plating system. The portfolio of innovative screws and low-profile plates expands for Smith & Nephew surgeon customers the variety of patients who can return to an active lifestyle after orthopaedic foot surgery.
Antigenics Inc. announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") on December 30, 2009 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
It is expected that the upcoming World Health Organisation's (WHO) annual assembly will be dominated this year by the emergence and spread of the new influenza virus H1N1 (swine flu).
Tyco International Ltd. today reported $0.55 in diluted earnings per share (EPS) from continuing operations for the fiscal fourth quarter of 2010 and diluted EPS from continuing operations before special items of $0.74 per share. Revenue in the quarter was $4.5 billion with organic revenue growth of 2% year-over-year. Cash from operating activities was $963 million and free cash flow was $598 million. These amounts included $39 million of cash outflows related to restructuring activities and acquisition-related costs.
The Foundation for Innovative New Diagnostics and Unitaid announced today that the organizations have launched a call for expressions of interest to accelerate the availability and manufacturing scale-up of rapid diagnostic tests for the detection of SARS-CoV-2 antigens. Reliable, affordable Ag RDTs have been identified as key tools in the global response to COVID-19, as they could enable robust detection of active SARS-CoV-2 infection for both patient management and contact tracing purposes in decentralized settings.
› Verified 7 days ago